AR109629A1 - Composiciones para la administración local de agonistas de receptores de tipo toll - Google Patents

Composiciones para la administración local de agonistas de receptores de tipo toll

Info

Publication number
AR109629A1
AR109629A1 ARP170102467A ARP170102467A AR109629A1 AR 109629 A1 AR109629 A1 AR 109629A1 AR P170102467 A ARP170102467 A AR P170102467A AR P170102467 A ARP170102467 A AR P170102467A AR 109629 A1 AR109629 A1 AR 109629A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
alkylene
alkenyl
aryl
Prior art date
Application number
ARP170102467A
Other languages
English (en)
Inventor
Janardhanan Anand Subramony
Alexander Schwarz
Amir Fakhari
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of AR109629A1 publication Critical patent/AR109629A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/16—Nitrogen-containing compounds
    • C08K5/34—Heterocyclic compounds having nitrogen in the ring
    • C08K5/3442—Heterocyclic compounds having nitrogen in the ring having two nitrogen atoms in the ring
    • C08K5/3445—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones que comprenden un polímero termosensible inverso, un modificador de la respuesta inmunitaria (IRM) y etanol. El polímero termosensible es poloxamer 407 o PLGA-PEG-PLGA. El IRM puede ser un agonista de receptor de tipo Toll (TLR), en particular, un agonista de TLR7, TLR8 o TLR7/8. Métodos. Usos. Reivindicación 1: Una composición que comprende: a) un 10% - 25% (p/v) de un polímero termosensible inverso; b) un modificador de la respuesta inmunitaria (IRM) de fórmula (1), en donde R¹ tiene la fórmula alquileno-L-R¹⁻¹, alquenileno-L-R¹⁻¹ o alquinileno-L-R¹⁻¹, en donde: los grupos alquileno, alquenileno y alquinileno están opcionalmente interrumpidos o terminados por uno o más grupos -O-; L es un enlace o un grupo enlazador funcional seleccionado entre el grupo que consiste en -NH-S(O)₂-, -NH-C(O)-, -NH-C(S)-, -NH-S(O)₂-NR³-, -NH-C(O)-NR³-, -NH-C(S)-NR³-, -NH-C(O)-O-, -O-, -S- y -S(O)₂-; y R¹⁻¹ es un grupo alifático lineal o ramificado que incluye opcionalmente uno o mas enlaces carbono-carbono insaturados; R se selecciona entre el grupo que consiste en hidrógeno, halógeno, hidroxi, alquilo, alquenilo, haloalquilo, alcoxi, alquiltio y -N(R³)₂; n es de 0 a 4; R² se selecciona entre el grupo que consiste en: hidrógeno; alquilo; alquenilo; arilo; heteroarilo; heterociclilo; alquilen-Y-alquilo; alquilen-Y-alquenilo; alquilen-Y-arilo; y alquilo o alquenilo sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en: -OH; halógeno; -N(R⁴)₂; -C(O)alquilo C₁₋₁₀; -C(O)-O-alquilo C₁₋₁₀; -N₃; arilo; heteroarilo; heterociclilo; -C(O)-arilo; y -C(O)-heteroarilo; Y es -O- o -S(O)₀₋₂-; cada R⁴ se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo C₁₋₁₀ y alquenilo C₂₋₁₀; y R³ se selecciona entre el grupo que consiste en hidrógeno y alquilo; con la condición de que cuando L es -NH-S(O₂)- y n es 0, R¹⁻¹ sea un grupo alifático lineal o ramificado que tiene al menos 16 átomos de carbono que incluye opcionalmente uno o más enlaces carbono-carbono insaturados; o una sal farmacéuticamente aceptable del mismo; y c) hasta un 20% (v/v) de etanol.
ARP170102467A 2016-09-08 2017-09-06 Composiciones para la administración local de agonistas de receptores de tipo toll AR109629A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662384922P 2016-09-08 2016-09-08

Publications (1)

Publication Number Publication Date
AR109629A1 true AR109629A1 (es) 2019-01-09

Family

ID=61561541

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102467A AR109629A1 (es) 2016-09-08 2017-09-06 Composiciones para la administración local de agonistas de receptores de tipo toll

Country Status (3)

Country Link
AR (1) AR109629A1 (es)
TW (1) TW201822767A (es)
WO (1) WO2018049017A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210141461A (ko) 2019-02-01 2021-11-23 캔웰 바이오테크 리미티드 이미다조퀴놀린 아민 유도체, 약제학적 조성물, 이의 용도
CN113730570A (zh) * 2019-09-26 2021-12-03 苏州百迈生物医药有限公司 一种化疗免疫组合药物及其应用
WO2022093658A1 (en) * 2020-11-01 2022-05-05 Tianxin Wang In situ vaccine for cancer cell and tumor treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
CA2578741C (en) * 2004-09-02 2014-01-14 3M Innovative Properties Company 1-alkoxy 1h-imidazo ring systems and methods
US20100028381A1 (en) * 2006-06-19 2010-02-04 3M Innovative Properties Company Formulation for delivery of immune response modifiers
US20160000890A1 (en) * 2013-03-15 2016-01-07 Biospecifics Technologies Corp. Thermosensitive hydrogel collagenase formulations
US10682415B2 (en) * 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
US9980956B2 (en) * 2014-08-01 2018-05-29 3M Innovative Properties Company Methods and therapeutic combinations for treating tumors

Also Published As

Publication number Publication date
TW201822767A (zh) 2018-07-01
WO2018049017A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
AR109629A1 (es) Composiciones para la administración local de agonistas de receptores de tipo toll
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR118123A2 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación
AR106605A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR109348A1 (es) Sulfonilureas y compuestos relacionados y sus usos
AR112414A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción benzotriazol, conjugados de estos y métodos y usos de estos
AR110405A1 (es) Compuestos
EA202091483A1 (ru) Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
AR100702A1 (es) Compuestos inhibidores de quinasa de unión tank
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR113826A1 (es) Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
BR122021005860A8 (pt) Derivados de aminoácidos e composição que os compreende
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR105337A1 (es) Producto de limpieza
AR094550A1 (es) Inhibidores de btk
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR110440A1 (es) Compuestos para el tratamiento de la enfermedad respiratoria bovina o porcina
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR090596A1 (es) Formulaciones farmaceuticas que comprenden antagonistas de ccr3
AR102544A1 (es) Compuestos derivados de dihidrohidantoína como herbicidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure